VSNL1 and type 2 diabetes mellitus: Effectors from this pathway included an sQTL for GLP1R, a major drug target for T2D [67], four members of the same protein interaction complex, and a novel T2D association for VSNL1, previously shown to stimulate cAMP production and insulin secretion [34].